Myelodysplastic syndromes in the United States: An update for clinicians

Annals of Medicine

Volumn 46, Issue 5, 2014, Pages 283-289

  Troy, Jesse D ^a   Atallah, Ehab ^b   Geyer, Julia T ^c   Saber, Wael ^b,d  

^a EMMES CORPORATION   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

Author keywords

Bone marrow diseases; Hematology; Leukemia; Malignancy; Myelodysplastic syndromes

Indexed keywords

ADJUVANT THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT INDICATION; UNITED STATES; ADVERSE EFFECTS; AGED; ANEMIA; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PROCEDURES;

AGED; ANEMIA; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84905448514     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.898863     Document Type: Review

References (65)

1. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in mye-lodysplastic syndromes. Nat Rev Cancer. 2012;12:849-59.
2. Scott BL, Deeg HJ. Myelodysplastic syndromes. Annu Rev Med. 2010; 61: 345-58.
3. Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S2-5.
4. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24: 287-94.
5. Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012; 36: 1441-52.
6. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112: 45-52.
7. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-88.
8. Malcovati L, Germing U, Kuendgen A, Della Porta M G, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-10.
9. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-51.
10. Pasquini M, Wang Z. Cur rent use and outcome of hematop oiet ic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org (accessed 12 August 2013).
11. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodys-plastic syndromes using a novel claims-based algorithm. Blood. 2011;117:7121-5.
12. Steensma DP. Are myelodysplastic syndromes 'cancer'? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006; 30: 1227-33.
13. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004; 104: 2263-8.
14. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28: 2847-52.
15. Bain BJ. Di Guglielmo and his syndromes. Br J Haematol. 2003;120: 939-43.
16. Hamilton-Paterson JL. Pre-leukaemic anaemia. Act a Haematol. 1949; 2: 309-16.
17. Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. J Am Med Assoc. 1953; 152: 1018-28.
18. Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med. 1973; 55: 38-48.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33: 451-8.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-99.
21. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-51.
22. Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009: 645-55.
23. Brunning R, Porwit A, Swerdlow S, Campo E. Myelodysplastic syndromes/neoplasms overview. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumors. 4th ed. Lyon: IARC; 2008. p. 88-93.
24. Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010; 10: 309-19.
25. Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol. 2013; 162: 587-605.
26. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364: 2496-506.
27. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013; 27: 1275-82.
28. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012; 366: 1090-8.
29. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-9.
30. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012; 26: 542-5.
31. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365: 1384-95.
32. Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 2013; 121: 3811-17.
33. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009; 114: 2764-73.
34. Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program. 2012;2012:183-90.
35. Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012;2012:191-7.
36. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplas-tic syndromes. Blood. 2012; 120: 2454-65.
37. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113: 1351-61.
38. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22: 538-43.
39. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:692-701.
40. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11: 838-74
41. Revised International Prognostic Scoring System (IPSS-R) for myelod-ysplastic syndromes risk assessment calculator: T e Myelodysplastic Syndromes Foundation. Available at: http://www.mds-foundation.org/ipss-r- calculator/(accessed 8 July 2013).
42. Cluzeau T, Mounier N, Richez V, Karsenti J-M, Legrand F, Mannone L, et al. Azacitidine overcomes prognosis impact of poor and very poor IPSS-Revised in RAEB-2 patients but not in AML patients. American Society for Hematology Annual Meeting; 8-11 December 2012; Atlanta, GA, USA. Abstract 2813.
43. Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, et al. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin Oncol. 2013;31:3557-64.
44. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011; 44: 53-7.
45. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30: 3376-82.
46. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European Leukemi-aNet. Blood. 2013; 122: 2943-64.
47. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
48. Gyurkocza B, Deeg HJ. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? Blood Rev. 2012;26:247-54.
49. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodys-plastic syndrome. J Clin Oncol. 2008;26:3607-13.
50. Fenaux P, Mufi GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-32.
51. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-40.
52. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987-96.
53. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-803.
54. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579-85.
55. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662-70.
56. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-70
57. Allogeneic hematopoietic stem cell transplantation for the treatment of myelodysplastic syndromes: Centers for Medicare and Medicaid Services. Available at: http://www.cms.gov/Medicare/Coverage/Cover-age-with-Evidence-Development/ Allogeneic-Hematopoietic-Stem-Cell-Transplantation-for-the-treatment-of- Myelodysplastic-Syndromes-. html (accessed 30 July 2013).
58. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(9 Suppl):8-15.
59. US transplant data by disease report: Center for International Blood and Marrow Transplant. Available from: http://bloodcell.transplant. hrsa.gov/RESEARCH/Transplant-Data/US-Tx-Data/Data-by- Disease/national.aspx (accessed 30 July 2013).
60. Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122:1974-82.
61. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Ef ect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878-87.
62. Atallah E, Pedersen T, Warlick E, Dircks A, Weisdorf D, Horowitz M, et al. The outcome of hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) in adults a 65 years of age: first report of the coverage with evidence development (CED) in Medicare beneficiaries. American Society for Hematology Annual Meeting; Atlanta, GA: American Society for Hematology Annual Meeting; 8-11 December 2012; Atlanta, GA, USA. Abstract 1983.
63. Atallah E, Bylow K, Troy J, Saber W Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic cell transplantation (allo HSCT). Curr Hematol Malig Rep. 2014; 9: 57-65.
64. Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, et al. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials. 2008; 5: 607-16
65. Warlick ED. Epidemiology of myelodysplastic syndromes: many questions remain. Leuk Lymphoma. 2011; 52: 163-4.